A collaboration between Viapath, NIHR Guy’s and St Thomas’ Biomedical Research Centre has created the world’s first nanopore-based genetic sequencing test for Huntington’s disease, now available at Guy’s and St Thomas’ hospitals. If successful, the test could cut waiting time for complicated Huntington’s cases, and could have big ramifications for other disorders in the future.
Disruptive science can have a significant impact outside of our own domains of research and into our personal lives. Keeping abreast of these developments can help prepare and inspire.
Heating solid tumours during CAR-T cell therapy could increase change of success, researchers from the UCLA Jonsson Comprehensive Cancer Center have found. Combining a heating technique called photothermal ablation with the infusion of CAR-T cells suppressed melanoma tumor growth for up to 20 days in mice.
Out of a whole host of engaging and enjoyable moments at Front Line Genomics’ recent Data Driven Drug Development (D4) conference, held in Boston on 20-21 March, one of the most memorable was definitely the triumph of nQ Medical in our innovation showcase, beating out three other contenders for the claim to be “most innovative” of the technologies on display.
Harvard College researchers have announced that more than 13,000 genetic alterations have been made to a single cell using CRISPR technology. This work is designed to edit genomes at a much larger scale than currently possible.
Oncology and precision medicine company Strata Oncology has announced the launch of its expanded StrataNGS test 3.0 for patients with advanced cancer. The test analyses 500 genes for three particular immunotherapy biomarkers, microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1, to better inform use of precision treatments.
For the first time, CRISPR-Cas9 has been combined with electronic graphene transistors to create a new handheld device which can detect specific mutations in the genome within minutes. The device can be used to quickly diagnose genetic disorders and diseases or determine the accuracy of gene-editing techniques.
Scientists from the University of California have announced a possible alternative option to electronic eye implants for those who have lost their sight: gene therapy. Virus-delivered genes for green opsin gave blind mice sight enough to determine patterns on an iPad, they found, with the therapy possibly ready for clinical trials in three years’ time.
The scientists of seven nations have called for a halt to gene-editing experiments seeking to alter heritable traits in human babies.
Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
A second individual has experienced sustained remission from HIV after their treatment ended, scientists from the University of Central London and Imperial College have found.
Biogen has announced it will acquire Nightstar Therapeutics for around $800m, providing the pharma giant with a pipeline of gene therapy candidates for ophthalmology.
Twins born in Australia have become the second-ever-identified pair of “semi-identical” twins, and the first to be detected before they were born. Such cases come about when twins receive 100% identical genes from their mother, but not from their father.